Concordance of programmed death-ligand 1 expression assessments determined via two immunohistochemical tests and the polymerase chain reaction method

Table 1 Inclusion and exclusion criteria for patients in the study

Inclusion criteria	Exclusion criteria
Stage breast cancer Tis-2N0-1M0	Chemotherapy, targeted, hormone therapy or radiation therapy before surgery
Radical surgical treatment (R0) at the first stage	Taking corticosteroids or nonsteroidal anti-inflammatory drugs
Axillary lymph node dissection at levels 1-2	Refusal to participate in the study
Voluntary informed consent to participate in a clinical trial